Showing posts with label TRPV1. Show all posts
Showing posts with label TRPV1. Show all posts

Tuesday, November 27, 2018

Pain Receptors and Diabetic Neuropathy

We Got the Markers
Our Markers for Pain Research are widely used and frequently published. They are often referenced in publications on Diabetic nerve pain.

Here are some of my past blog postings:
Here's a model of the actual nerve receptors behind both intractable pain and loss of sensation.
A: Simplified model of nociception under normal conditions. Free nerve endings transduce a painful stimulus into a neural signal, which propagates to DRG centrally and eventually synapses on a nociceptive neuron within the DH of the spinal cord.B: Proposed model of nociception under conditions of diabetic hyperalgesia and allodynia. A pain signal augmented by upregulated pronociceptive ion channels in sensory neurons is carried toward the DH, where it is further augmented by a hypoactive GABAergic system and subsequently diminished inhibition from an inhibitory interneuron. NMDAR, N-Methyl-D-aspartate receptors. https://doi.org/10.2337/dbi15-0006
We will continue to post findings on the root causes and potential treatment for Neuropathy.

Monday, May 15, 2017

TRPV1 Antibodies

Designed for Your Success.
The roots of our TRPV1 Antibodies run deep. They have been key to our ongoing success. We have been providing them to Researchers since the inception of Neuromics (12 years ago).

We measure our success one Researcher at a time. Positive feedback includes references in many publications. There are indeed "Tested; Characterized and Research Ready"

Here's a pub hot off the presses: Noémi Bohonyi, Krisztina Pohóczky, Bálint Szalontai, Anikó Perkecz, Krisztina Kovács, Béla Kajtár, Lajos Orbán, Tamás Varga, Sarolta Szegedi, József Bódis, Zsuzsanna Helyes, Miklós Koppán. Local upregulation of transient receptor potential ankyrin 1 and transient receptor potential vanilloid 1 ion channels in rectosigmoid deep infiltrating endometriosis. Molecular Pain. First published date: May-07-2017. 10.1177/1744806917705564.
Figure: Immunohistochemical staining of TRPV1 receptor in healthy eutopic endometrium and in rectosigmoid DIE nodules. (a) Negative control using tris-buffered saline instead of the primary antibody in normal endometrial tissue. (b) Rectal myenteric ganglia, serving as positive control for TRPA1 expression. (c) Healthy eutopic endometrial tissue. (d) Rectosigmoid DIE nodule. (e) Rectosigmoid DIE nodule, glandular component. (f) Rectosigmoid DIE nodule, stromal component. (d) and (f) Sections shown on panels were taken from the same DIE patient who experienced severe, endometriosis associated pain. Background staining was performed with hematoxylin and eosin to reveal the tissue structure. Black arrow heads denote TRPV1 receptor labelling. Magnification is X400, except panel (d) where it is X100. Scale bars: 50 µm, except panel (d) where it is 200 µm.
We frequently post unique data generated by use of our antibodies.

Saturday, May 11, 2013

Tissue Acidosis and Inflammation Related Nociceptive Pain

Important Implications for Inflammatory Pain States

Inflammatory pain is often accompanied by a drop in pH (Acidosis). Here investigators hypothesized that modest drops in extracellular pH leading to calcium fluxes acts like a dynamic switch to rapidly mobilize trkA to the cell membrane surface of adult sensory neurons, which in turn serves to increase the sensitivity of these neurons to NGF. The findings reveal a cellular mechanism whereby even small changes in pH can rapidly shift sensitivity to a critical driver of the inflammatory pain state—NGF. They way they demonstrate this shift is quite ingenious: Geoffrey E. Bray, Zhengxin Ying, Landon D. Baillie, Ruiling Zhai, Sean J. Mulligan, and Valerie M.K. Verge. Extracellular pH and Neuronal Depolarization Serve as Dynamic Switches to Rapidly Mobilize trkA to the Membrane of Adult Sensory Neurons. The Journal of Neuroscience, 8 May 2013, 33(19):8202-8215; doi:10.1523/JNEUROSCI.4408-12.2013.
Images: NGF-responsive adult sensory neurons have a large cytoplasmic pool of high-affinity NGF receptors. Six micrometer cryostat sections of L5 DRG processed for high-affinity NGF binding (left) or trkA immunohistochemistry (right) reveal a large cytoplasmic pool of proteins that are able to bind 20 pm radio-iodinated NGF with high affinity or that are immunoreactive to trkA-selective antibodies. Scale bar, 20 μm.

Here're images showing the pH Related switch and rapid migration of TrkA to the membrane

Images: Acidic pH challenge rapidly mobilizes trkA to the membrane from internal stores. A, Bar graphs summarize relative changes in neuronal cell-surface trkA expression from three separate experiments (detected with immunofluorescence) over neurons exposed to control (pH 7.4) or acidic (pH 6.5) media for 30 min with or without exposure to Golgi collapsing compound BFA and as normalized to the mean signal intensity from the control pH group. Note: A significant increase is observed in the mean levels of trkA mobilized to the neuronal membranes of sensory neurons in response to acidosis when compared with the control pH, a response that is blocked with BFA treatment. B, Immunofluorescence photomicrographs and summary histograms (C) depict degree of FM 1–43FX-stained neuronal membrane internalization in response to conditions as indicated. Note: Significant membrane internalization was only observed in the NGF challenge control group and not in response to acidic pH challenge with or without BFA treatment. (Data normalized to the control pH of each experimental condition and pooled from three separate experiments; A, C, one-way ANOVA with post hoc Tukey's, **< 0.01; ***< 0.001). Scale bar, 20 μm.

The heightened level of trkA activation likely has ramifications on both short- and long-term sensitization processes as it regulates the activity and expression of a wide variety of receptors, ion channels, and signaling molecules (Mantyh et al., 2011). In the short term, it modulates the activity of receptors and ion channels. For example, NGF decreases the threshold of activation of the nociceptive transient receptor potential vanilloid 1 (TRPV1) receptors (Chuang et al., 2001), mediates TRPV1 trafficking to the membrane (Stein et al., 2006), increases purinergic receptor P2X3-mediated currents and Ca2+ transients (D'Arco et al., 2007) and for sympathetic neurons, rapidly modulates the activity of at least four voltage-gated currents (Luther and Birren, 2009). In the long term, increased NGF can lead to increased transcription of many nociception-associated genes such as its receptors trkA and p75 (Verge et al., 1989, 1992); the neuropeptides Substance P, calcitonin gene-related peptide (Lindsay and Harmar, 1989; Verge et al., 1995), and PACAP; Jongsma Wallin et al., 2001, 2003); sodium channels (Dib-Hajj et al., 1998; Fjell et al., 1999; Kerr et al., 2001); and P2X3 (Ramer et al., 2001; Simonetti et al., 2006). It is also interesting to note that activation of trkA was linked in our study to a parallel activation of p38MAPK, which has been shown to be linked to NGF-mediated increases in ASIC3 expression during inflammation (Mamet et al., 2003).

Related Reagents:
All Trk Antibodies
Neurotrophin Antibodies
Neurotrophin Proteins
Primary Neurons and Astrocytes-Primary human, rat and mouse neurons and astrocytes by Category


        

Monday, April 22, 2013

Small Molecules-Peptides for Neuroscience Research

Agonists, Antagonists, Inhibitors and Ligands for Studying Neuromodulation

Our friends at R and D Systems/Tocris Bioscience have made available to us select Small Molecules/Peptides. Our focus will be on providing agonists, antagonists, inhibitors and ligands that complement our Neuroscience and Pain Research products and expertise.



We will be adding about 10 new molecules/peptides per month. Here's a sampling our our most recent additions:
NameTypeBioactivity
(±)-trans-ACPDAgonistPotent NMDA agonist. Also group II mGluR agonist
(S)-(-)-5-FluorowillardiineAgonistVery potent AMPA agonist
(S)-4-CarboxyphenylglycineAntagonistCompetitive group I mGluR antagonist/weak group II agonist
2-APBModulatorTRP channel modulator. Also IP3 receptor antagonist
2-Methylthioadenosine triphosphate tetrasodium saltAgonistP2 purinergic agonist
AM 404ModulatorVanilloid receptor agonist. Also anandamide transport inhibitor
BRL 52537 hydrochlorideLigandPotent and selective κ opioid receptor agonist
CNQXAntagonistPotent AMPA/kainate antagonist
Clocinnamox mesylateAntagonistIrreversible μ-opioid receptor antagonist
Endomorphin-1AgonistPotent and selective μ opioid receptor agonist
Endomorphin-2AgonistPotent and selective μ opioid receptor agonist
FITAgonistIrreversible δ opioid receptor agonist
GBR 13069 dihydrochlorideAgonistPotent dopamine uptake inhibitor
L-NIO dihydrochlorideInhibitorPotent eNOS inhibitor
L-Quisqualic acidAgonistVery potent group I mGluR agonist
N-Benzylnaltrindole hydrochlorideAgonistOpioid receptor selective non-peptide antagonist
NociceptinInhibitorEndogenous NOP agonist
O-Phospho-L-serineAntagonistGroup III mGluR agonist; enhances neuronal differentiation
Ro 51AntagonistPotent P2X3, P2X2/3 antagonist
cis-ACPDAgonistPotent NMDA agonist. Also group II mGluR agonist
We will be posting new additions and related data and publications

Sunday, May 20, 2012

Cannabinoid Type-1 Receptors and Chemotherapy Related Pain

Chemotherapy can induce painful peripheral neuropathy and also have a toxic effect on peripheral nerves. The authors here show that that cisplatin produces hyperalgesia and toxicity to sensory neurons as indicated by neurochemical, morphological, and functional measures. Increasing AEA signaling at CB1 receptors not only reduced the hyperalgesia but reduced the neurotoxicity of cisplatin as well:  Iryna A. Khasabova,Sergey Khasabov, Justin Paz, Catherine Harding-Rose, Donald A. Simone, and Virginia S. Seybold. Cannabinoid Type-1 Receptor Reduces Pain and Neurotoxicity Produced by Chemotherapy. The Journal of Neuroscience, 16 May 2012, 32(20): 7091-7101; doi: 10.1523/​JNEUROSCI.0403-12.2012.

The authors use our guinea pig TRPV1 antibody to measure cisplatin hyperalgesia vs treated and control mice.

Images: URB597 attenuated effects of cisplatin on protein expression in DRGs. A, TRPV1- and ATF-3-ir were detected by immunofluorescence in L3–L5 DRGs from mice treated with vehicle, cisplatin, or cisplatin plus URB597. Cisplatin (1 mg/kg of body weight, daily for 7 d, i.p.) increased the occurrence of TRPV1- and ATF3-ir in neurons. Co-injection of URB597 (0.3 mg/kg daily, i.p.) with cisplatin attenuated the effect cisplatin on protein-ir. Scale bars: 10 μm (for images within each antigen). B, Quantitative summary of the effect of treatments on TRPV1-ir in neurons. Data are expressed as the mean ± SEM. aSignificantly different from each other group (p < 0.05, one-way ANOVA with Student–Newman–Keuls test; n = 4 mice/treatment). C, Quantitative summary of the effect of treatments on ATF-ir in neurons. Data are expressed as the median and 25th and 75th percentile range. *Significantly different from vehicle control and cisplatin plus URB597 groups (n = 6 mice/treatment; p < 0.001, Kruskal–Wallis ANOVA on ranks test).

Related Reagents:

VR1 N-Terminus (TRPV1)
VR1 (TRPV1)-Goat
VR1 C-Terminus (TRPV1) - mouse specific
All TRP Antibodies
Pain and Inflammation Research Antibodies
Neurotransmission -Neurotransmission Research Antibody Categories